{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:18:09Z","timestamp":1791670689067,"version":"4.3.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107516","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T15:00:58Z","timestamp":1412002858000},"page":"e107516","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":109,"title":["Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies"],"prefix":"10.1371","volume":"9","author":[{"given":"Jinsheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,29]]},"reference":[{"key":"ref1","unstructured":"(2014) FDA drug safety communication: FDA requests label changes and single-use packaging for some over-the-counter topical antiseptic products to decrease risk of infection. Clin Infect Dis 58: i\u2013ii."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3322\/canjclin.22.4.232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"C Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1126\/science.156.3778.1050","article-title":"Endocrine-induced regression of cancers","volume":"156","author":"C Huggins","year":"1967","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"CS Saigal","year":"2007","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"NL Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"SM Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"PL Nguyen","year":"2011","journal-title":"JAMA"},{"key":"ref8","volume":"307","unstructured":"Blankfield RP (2012) Androgen deprivation therapy for prostate cancer and cardiovascular death. JAMA <volume>307<\/volume>: : 1252; author reply 1252\u20131253."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"JA Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"EM Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","article-title":"Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial)","volume":"55","author":"FH Schroder","year":"2009","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"UE Studer","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"NL Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref14","unstructured":"Schulz KF, Grimes DA (2006) The Lancet handbook of essential concepts in clinical research: Elsevier London."},{"key":"ref15","unstructured":"Wells GA, Shea B, O&apos; Connell D, Peterson J, Welch V, <etal>et al<\/etal>.. (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa Hospital Research Institute Web site."},{"key":"ref16","first-page":"489","article-title":"GRADE: levels of evidence and grades of recommendation","volume":"89","author":"B Phillips","year":"2004","journal-title":"Arch Dis Child"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-13-332","article-title":"Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies","volume":"13","author":"S Zhu","year":"2013","journal-title":"BMC Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.apmr.2006.04.006","article-title":"Systematic reviews on rehabilitation interventions","volume":"87","author":"HH Handoll","year":"2006","journal-title":"Arch Phys Med Rehabil"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"HK Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","article-title":"Androgen deprivation therapy and cardiovascular risk","volume":"29","author":"S Punnen","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, <etal>et al<\/etal>.. (2014) The Impact of the Androgen Deprivation Therapy on the Risk of Coronary Heart Disease in Patients with Non-Metastatic Prostate Cancer: A Population-Based Study. BJU Int.","DOI":"10.1111\/bju.12732"},{"key":"ref25","first-page":"1518","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"104","author":"NL Keating","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.26022","article-title":"Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden","volume":"130","author":"D Robinson","year":"2012","journal-title":"Int J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2011.09.010","article-title":"Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden","volume":"61","author":"M Van Hemelrijck","year":"2012","journal-title":"Eur Urol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"M Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2006.01.030","article-title":"Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy","volume":"65","author":"GS Merrick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"529468","DOI":"10.1155\/2014\/529468","article-title":"Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate","volume":"2014","author":"G Huang","year":"2014","journal-title":"J Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2010.03.018","article-title":"Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency","volume":"80","author":"J Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"E Martin-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Jespersen CG, Norgaard M, Borre M (2013) Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study. Eur Urol.","DOI":"10.1016\/j.eururo.2013.02.002"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.3748\/wjg.v19.i25.4053","article-title":"Probiotics improve survival of septic rats by suppressing conditioned pathogens in ascites","volume":"19","author":"DQ Liu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0002-9343(01)00833-6","article-title":"Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis","volume":"111","author":"EA Whitsel","year":"2001","journal-title":"Am J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2164\/jandrol.108.007245","article-title":"The dark side of testosterone deficiency: III. Cardiovascular disease","volume":"30","author":"AM Traish","year":"2009","journal-title":"J Androl"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1210\/jc.2007-1792","article-title":"Low serum testosterone and mortality in older men","volume":"93","author":"GA Laughlin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2265.2005.02339.x","article-title":"Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis","volume":"63","author":"AM Isidori","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.0.1500065","article-title":"Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study","volume":"150","author":"J Svartberg","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/j.1550-8528.1993.tb00618.x","article-title":"Androgen treatment of abdominally obese men","volume":"1","author":"P Marin","year":"1993","journal-title":"Obes Res"},{"key":"ref41","first-page":"412","article-title":"Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men","volume":"122","author":"CJ Glueck","year":"1993","journal-title":"J Lab Clin Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/01.RES.84.7.813","article-title":"Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits","volume":"84","author":"P Alexandersen","year":"1999","journal-title":"Circ Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0021-9150(93)90053-W","article-title":"Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels","volume":"99","author":"BA Larsen","year":"1993","journal-title":"Atherosclerosis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1161\/CIRCULATIONAHA.107.708768","article-title":"Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor","volume":"116","author":"JE Nettleship","year":"2007","journal-title":"Circulation"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer","volume":"8","author":"PJ Saylor","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MED.0b013e32814db88c","article-title":"Androgen deprivation therapy for prostate cancer: new concepts and concerns","volume":"14","author":"MR Smith","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"V Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"RE Langley","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T11:23:20Z","timestamp":1565868200000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107516"}},"subtitle":[],"editor":[{"given":"Natasha","family":"Kyprianou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,29]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107516","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,29]]}}}